Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.
David J. Kwiatkowski(Brigham and Women's Hospital), David J. Sugarbaker(Brigham and Women's Hospital), John J. Godleski(Boston University), Dar-Bin Shieh, James E. Herndon(Duke University), Gary M. Strauss, William G. Richards(University of Oxford), Hong Xu(Institute of Biophysics), Rosa Blanco, David H. Harpole(Duke Medical Center)
Cited by 188
Related Papers
Cardiovascular Mortality and Long-Term Exposure to Particulate Air Pollution
|Circulation|2003|2.6k
Bayesian kernel machine regression for estimating the health effects of multi-pollutant mixtures
|Biostatistics|2014|1.8k
Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
|JAMA Oncology|2018|689